The Indian government is doling out ₹1500 crore to reserve 300 million of Biological-E’s COVID-19 vaccine doses
- The Indian government is booking 300 million doses of
Biological-E’s COVID-19 vaccinein advance in the face of a massive shortage.
- Biological-E’s candidate will be the second ‘made-in-India’ vaccine to hit the market after
- The government is shelling out a massive ₹1500 crore to secure the doses.
In a bid to meet the increasing demand for the Coronavirus vaccine, the Indian government is shelling out ₹1,500 crore to secure 300 million doses of Biological-E’s
View all Offers
View all Offers
OnePlus Nord 2 5G (Blue Haze, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
- 18% OFF
Redmi 9A (Nature Green, 2GB RAM, 32GB Storage) | 2GHz Octa-core Helio G25 Processor | 5000 mAh Battery₹ 6999₹ 8499Buy On
OnePlus Nord 2 5G (Gray Sierra, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
- 19% OFF
Redmi Note 10 (Aqua Green, 4GB RAM, 64GB Storage) -Amoled Dot Display | 48MP Sony Sensor IMX582 | Snapdragon 678 Processor₹ 12999₹ 15999Buy On
- 18% OFF
Redmi 9 (Carbon Black, 4GB RAM, 64GB Storage) | 2.3GHz Mediatek Helio G35 Octa core Processor₹ 8999₹ 10999Buy On
The price of Biological-E’s vaccine is not publicly known, but according to the company, it is aiming to be one of the ‘ most affordable’ options in the country.
TOP VIDEOS FOR YOUThis will be the second domestically developed vaccine to hit the market, once approved, after Bharat Biotech’s Covaxin. The vaccine candidate, which is modelled after the Hepatitis E vaccine, is currently undergoing Phase III of its clinical trials.
“The proposal of M/s Biological-E was examined and recommended for approval after due diligence by National Expert Group on Vaccine Administration for COVID-19 (NEGVAC),” said the
Biological-E is developing the vaccine in association with the Baylor College of Medicine in the US and already has two agreements in place to manufacture the vaccine in India — one with Canada-based Providence Therapeutics Holdings and another with Johnson & Johnson.
Bharat Biotech and the
AdvertisementAccording to India’s Ministry of Health and Family Welfare (MoHFW), the Hyderabad-based pharmaceutical company will start manufacturing and stockpiling doses somewhere between August and December 2021.
Huawei announces first devices with HarmonyOS — set to take on Apple and Google with its in-house operating system
OnePlus Nord CE 5G full specifications leaked days ahead of launch – heavily inspired by the original Nord
- Here’s how brands can avoid making our athletes’ win at Tokyo Olympics all about themselves
- Tokyo Olympics: India beat Argentina 3-1 to enter the quarters in men's hockey
- Sony sells more than 10 million units of the PS5 despite supply shortage since launch
- From Adani Group to Tata Motors and banks — these 17 stocks have already lost over 10% in last one month
- Google, Amazon, IBM and many more are hiring business analysts across the country